ClinicalTrials.gg
TerminatedNCT01295060Updated Sep 20, 2013

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

A Phase 3 interventional study of Octreotide in Acromegaly, sponsored by Endo Pharmaceuticals. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-20.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Why this study was terminated
Program was terminated for business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
23rd of 25
12 · median 56
Started
2011
the only one that year
Phase 3
12 of 25
1 open now
Registered
14th of 25
by date
Lead sponsor
3 of 25
Endo Pharmaceuticals

Among the 25 studies testing octreotide in Acromegaly, this one is the 23rd largest by enrollment, is the only one that started in 2011, is one of 12 in phase 3, and was the 14th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide Implant in patients that were previously treated with an Octreotide implant.

Read the detailed description

Evaluation on the long-term safety and tolerability, including local tolerability of the implant site, of the 84-mg octreotide hydrogel implant in subjects with acromegaly who had been successfully treated with the 84-mg octreotide hydrogel implant in the Phase III study IP107-001.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Acromegaly
  • Octreotide
  • IGF-1
  • Growth Hormone
  • Implant
  • Hydrogel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently enrolled in the Extension Phase of Study IP107-001 and received at least one 84-mg octreotide hydrogel implant prior to enrollment OR previously enrolled in the Extension Phase of Study IP107-001 and currently taking lanreotide or octreotide.
  • Subjects who have been successfully treated with the 84-mg octreotide hydrogel implant in Study IP107 001.
  • In the opinion of the Investigator; subject has no unstable chronic medical conditions and no findings that would preclude subject's participation in the study.
  • Subjects must be able to communicate, provide and sign written , and be willing to participate and comply with study requirements.

Exclusion criteria

Exclusion Criteria:

  • Pituitary surgery less than 3 months prior to enrollment into this study
  • Liver disease (eg, cirrhosis, chronic active or persistent hepatitis or persistent abnormalities of , AST [level >2× normal] or direct [level >1.5× normal])
  • Unstable angina, sustained ventricular arrhythmias or heart failure ( III and IV)
  • Acute myocardial infarction within 3 months of Screening
  • Uncontrolled diabetes defined as having an ≥9%
  • Symptomatic cholelithiasis
  • History of drug or alcohol abuse
  • Received any drug or participated in another clinical trial except for study IP107 001 within 30 days of enrollment into this study
  • Received radiotherapy for pituitary tumor or any radiotherapy above the neck at any time prior to enrollment into this study
  • Receiving pegvisomant, dopamine agonist or other therapy in combination with somatostatin to control GH or IGF-1 levels prior to enrollment into this study
  • History or presence of significant cardiovascular, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease, any other severe coexisting or, terminal systemic disease that limits , or may interfere with the conduct of the study, or subjects who are incarcerated in penal institutions or are committed to mental institutions
  • Women who are pregnant or lactating. For females of , a positive pregnancy test prior to enrollment, or an unwillingness to use accepted forms of reliable for study duration (including bilateral tubal ligation, use of oral contraceptives, double barrier methods [diaphragm with spermicidal gel or condoms with contraceptive foam], Depo-Provera®, hormonal implants, partner vasectomy, and total abstinence). Pregnancy tests are not required (indicate "n/a") for males, or for females not of childbearing potential ( with last menstrual period >1 year ago or total hysterectomy with bilateral oophorectomy)
  • An unwillingness on the part of a male subject to abstain from sexual intercourse with pregnant or lactating women or an unwillingness to use a condom and spermicide and another form of contraception (eg, IUD, birth control pills taken by female partner, diaphragm with spermicide) if engaging in sexual intercourse with a woman who could become pregnant until discharge from the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Octreotide Implant

    Drug: Octreotide

Interventions

06

What researchers measure

Primary outcomes

  1. Long term safety and tolerability of the Octreotide Implant

    Subjects will be assessed every 3 months via adverse event reporting and examination of the implantation site

    Time frame: every 3 months for up to 2 years

Secondary outcomes

  1. Evaluate the long term efficacy of the Octreotide Implant

    Patients will have GH and IGF-1 analyzed every 3 months

    Time frame: every 3 months for up to 2 years

07

Study locations

6 sites
  • Denver, Colorado 80220, United States
  • Chicago, Illinois 60611, United States
  • Baltimore, Maryland 21215, United States
  • Cleveland, Ohio 44195, United States
  • Portland, Oregon 97239, United States
  • Seattle, Washington 98122, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Apr 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2011
First posted
Feb 14, 2011
Start
Feb 2011
Primary completionActual
Apr 2012
CompletionActual
Jun 2012
Results delay requested
Sep 9, 2013
Last update
Sep 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01295060
Responsible party
Sponsor
First posted
Feb 14, 2011
Start date
Feb 2011
Primary completion
Apr 2012
Completion
Jun 2012
Last update
Sep 20, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion